732 related articles for article (PubMed ID: 19720878)
1. Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.
Gu W; Yan H; Winters KA; Komorowski R; Vonderfecht S; Atangan L; Sivits G; Hill D; Yang J; Bi V; Shen Y; Hu S; Boone T; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2009 Dec; 331(3):871-81. PubMed ID: 19720878
[TBL] [Abstract][Full Text] [Related]
2. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys.
Yan H; Gu W; Yang J; Bi V; Shen Y; Lee E; Winters KA; Komorowski R; Zhang C; Patel JJ; Caughey D; Elliott GS; Lau YY; Wang J; Li YS; Boone T; Lindberg RA; Hu S; Véniant MM
J Pharmacol Exp Ther; 2009 Apr; 329(1):102-11. PubMed ID: 19129372
[TBL] [Abstract][Full Text] [Related]
3. Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys.
Okamoto H; Kim J; Aglione J; Lee J; Cavino K; Na E; Rafique A; Kim JH; Harp J; Valenzuela DM; Yancopoulos GD; Murphy AJ; Gromada J
Endocrinology; 2015 Aug; 156(8):2781-94. PubMed ID: 26020795
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse.
Bahrami J; Longuet C; Baggio LL; Li K; Drucker DJ
Gastroenterology; 2010 Sep; 139(3):857-68. PubMed ID: 20546737
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of glucagon secretion.
Young A
Adv Pharmacol; 2005; 52():151-71. PubMed ID: 16492545
[TBL] [Abstract][Full Text] [Related]
6. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors.
Sloop KW; Cao JX; Siesky AM; Zhang HY; Bodenmiller DM; Cox AL; Jacobs SJ; Moyers JS; Owens RA; Showalter AD; Brenner MB; Raap A; Gromada J; Berridge BR; Monteith DK; Porksen N; McKay RA; Monia BP; Bhanot S; Watts LM; Michael MD
J Clin Invest; 2004 Jun; 113(11):1571-81. PubMed ID: 15173883
[TBL] [Abstract][Full Text] [Related]
7. Reduction of oxidative stress by a new low-molecular-weight antioxidant improves metabolic alterations in a nonobese mouse diabetes model.
Novelli M; D'Aleo V; Lupi R; Paolini M; Soleti A; Marchetti P; Masiello P
Pancreas; 2007 Nov; 35(4):e10-7. PubMed ID: 18090226
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice.
Gu W; Lloyd DJ; Chinookswong N; Komorowski R; Sivits G; Graham M; Winters KA; Yan H; Boros LG; Lindberg RA; Véniant MM
J Pharmacol Exp Ther; 2011 Jul; 338(1):70-81. PubMed ID: 21471191
[TBL] [Abstract][Full Text] [Related]
9. Increased responses of glucagon and glucose production to hypoglycemia with intraperitoneal versus subcutaneous insulin treatment.
Wan CK; Giacca A; Matsuhisa M; El-Bahrani B; Lam L; Rodgers C; Shi ZQ
Metabolism; 2000 Aug; 49(8):984-9. PubMed ID: 10954014
[TBL] [Abstract][Full Text] [Related]
10. Beta-cell function and mass in type 2 diabetes.
Larsen MO
Dan Med Bull; 2009 Aug; 56(3):153-64. PubMed ID: 19728971
[TBL] [Abstract][Full Text] [Related]
11. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
Sullivan TJ; Miao Z; Zhao BN; Ertl LS; Wang Y; Krasinski A; Walters MJ; Powers JP; Dairaghi DJ; Baumgart T; Seitz LC; Berahovich RD; Schall TJ; Jaen JC
Metabolism; 2013 Nov; 62(11):1623-32. PubMed ID: 23953944
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition.
Singh V; Grötzinger C; Nowak KW; Zacharias S; Göncz E; Pless G; Sauer IM; Eichhorn I; Pfeiffer-Guglielmi B; Hamprecht B; Wiedenmann B; Plöckinger U; Strowski MZ
Endocrinology; 2007 Aug; 148(8):3887-99. PubMed ID: 17525126
[TBL] [Abstract][Full Text] [Related]
13. Glucagon antagonism as a potential therapeutic target in type 2 diabetes.
Bagger JI; Knop FK; Holst JJ; Vilsbøll T
Diabetes Obes Metab; 2011 Nov; 13(11):965-71. PubMed ID: 21615669
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 21 (FGF21) and glucagon-like peptide 1 contribute to diabetes resistance in glucagon receptor-deficient mice.
Omar BA; Andersen B; Hald J; Raun K; Nishimura E; Ahrén B
Diabetes; 2014 Jan; 63(1):101-10. PubMed ID: 24062250
[TBL] [Abstract][Full Text] [Related]
15. Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes.
Yang SJ; Choi JM; Kim L; Kim BJ; Sohn JH; Kim WJ; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Kim SW; Park CY
Biochem Biophys Res Commun; 2011 Apr; 407(1):153-7. PubMed ID: 21371430
[TBL] [Abstract][Full Text] [Related]
16. Cloning and expression of canine glucagon receptor and its use to evaluate glucagon receptor antagonists in vitro and in vivo.
Yang X; Yates ML; Candelore MR; Feeney W; Hora D; Kim RM; Parmee ER; Berger JP; Zhang BB; Qureshi SA
Eur J Pharmacol; 2007 Jan; 555(1):8-16. PubMed ID: 17140563
[TBL] [Abstract][Full Text] [Related]
17. Increasing glucagon secretion could antagonize the action of exogenous insulin for glycemic control in streptozocin-induced diabetic rhesus monkeys.
He S; Wang D; Lu Y; Chen Y; Jin X; Wang C; Zhao J; Ren Y; Wang L; Li H; Cheng J
Exp Biol Med (Maywood); 2013 Apr; 238(4):385-91. PubMed ID: 23760004
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice.
Katsuno K; Fujimori Y; Ishikawa-Takemura Y; Isaji M
Eur J Pharmacol; 2009 Sep; 618(1-3):98-104. PubMed ID: 19615995
[TBL] [Abstract][Full Text] [Related]
19. Human monoclonal antibodies against glucagon receptor improve glucose homeostasis by suppression of hepatic glucose output in diet-induced obese mice.
Kim WD; Lee YH; Kim MH; Jung SY; Son WC; Yoon SJ; Lee BW
PLoS One; 2012; 7(12):e50954. PubMed ID: 23226550
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of brain-derived neurotrophic factor on pancreatic islets in obese diabetic mice.
Yamanaka M; Itakura Y; Inoue T; Tsuchida A; Nakagawa T; Noguchi H; Taiji M
Metabolism; 2006 Oct; 55(10):1286-92. PubMed ID: 16979397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
